ClinicalTrials.gg
CompletedNCT00783484Updated Jun 2, 2009

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

A Phase 1 interventional study of PF-03716539 and PF-03716539 in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-06-02.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

First in human study to evaluate the safety, tolerability, and pharmacokinetics of PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam, darunavir and maraviroc will also be evaluated.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • First in Human (FIH), PF-03716539, PK enhancer
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

(BMI) of approximately 18 to 30 kg/m2. Total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

Pregnant or nursing females. females of . Evidence or history of hematological, renal (including kidney stones), endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or clinical findings at screening.

Treatment with an drug within 30 days (or determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Cohort 1

    PF-03716539 crossover, single dose escalation (doses subject to change).

    Drug: PF-03716539 · Other: Placebo

  • Experimental
    Cohort 2

    PF-03716539 crossover, single dose escalation (doses subject to change).

    Drug: PF-03716539 · Other: Placebo

  • Experimental
    Cohort 3

    Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).

    Drug: Midazolam · Drug: Midazolam + PF-03716539 (100 mg) · Drug: Midazolam + PF-03716539 (50 mg)

  • Experimental
    Cohort 4

    Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).

    Drug: Darunavir · Drug: Darunavir + PF-03716539

  • Experimental
    Cohort 5

    Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).

    Drug: Maraviroc · Drug: Maraviroc +PF-03716539

  • Experimental
    Cohort 6

    Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).

    Drug: Maraviroc · Drug: Maraviroc +PF-03716539

Interventions

  • DrugPF-03716539

    PF-03716539 10 mg oral solution, single dose

  • DrugPF-03716539

    PF-03716539 25 mg oral solution, single dose

  • DrugPF-03716539

    PF-03716539 3 mg oral solution, single dose

  • OtherPlacebo

    Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)

  • DrugPF-03716539

    PF-03716539 100 mg oral solution, single dose

  • DrugPF-03716539

    PF-03716539 200 mg oral solution, single dose

  • DrugPF-03716539

    PF-03716539 50 mg oral solution, single dose

  • OtherPlacebo

    Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)

  • DrugMidazolam

    Midazolam 1 mg IV, single dose

  • DrugMidazolam + PF-03716539 (100 mg)

    Drug page: Midazolam

    Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose

  • DrugMidazolam + PF-03716539 (50 mg)

    Drug page: Midazolam

    Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose

  • Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)

  • DrugDarunavir + PF-03716539

    Drug page: Darunavir

    Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)

  • Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)

    Also known as: Selzentry

  • DrugMaraviroc +PF-03716539

    Drug page: Maraviroc

    Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)

    Also known as: Selzentry

  • Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)

    Also known as: Selzentry

  • DrugMaraviroc +PF-03716539

    Drug page: Maraviroc

    Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)

    Also known as: Selzentry

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of escalating single oral doses of PF 03716539 administered as Extemporaneous Powder for Solution (EPS) in healthy adult subjects.

    Time frame: 27 days

  2. To explore the pharmacokinetics of escalating single oral doses of PF 03716539 in healthy adult subjects.

    Time frame: 6 days

Secondary outcomes

  1. To assess the potency of PF 03716539 for CYP3A4 inhibition utilizing single dose IV midazolam as a probe substrate for CYP3A4/5.

    Time frame: 6 days

  2. To evaluate the potential of PF 03716539 to enhance or "boost" the pharmacokinetics of both darunavir and maraviroc.

    Time frame: 8 days

07

Study locations

1 site
  • Pfizer Investigational Site
    Bruxelles, 1070, Belgium
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Oct 31, 2008
Start
Oct 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Last update
Jun 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00783484
Lead sponsor
Pfizer
First posted
Oct 31, 2008
Start date
Oct 2008
Primary completion
May 2009
Completion
May 2009
Last update
Jun 2, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Darunavir · Maraviroc

Start the discussion